Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection.
about
CCR5, GPR15, and CXCR6 are major coreceptors of human immunodeficiency virus type 2 variants isolated from individuals with and without plasma viremiaGalectin-1-specific inhibitors as a new class of compounds to treat HIV-1 infectionMechanisms and modifications of naturally occurring host defense peptides for anti-HIV microbicide developmentEvidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusionAnti-HIV drug development through computational methods.Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro.CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from alpha-defensin-1 HIV inhibitionIntracellular CXCR4⁺ cell targeting with T22-empowered protein-only nanoparticles.Multifaceted mechanisms of HIV-1 entry inhibition by human α-defensinNatural antimicrobial peptides as promising anti-HIV candidates.The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.Exploratory studies on development of the chemokine receptor CXCR4 antagonists toward downsizing.Replacement of the V3 region of gp120 with SDF-1 preserves the infectivity of T-cell line-tropic human immunodeficiency virus type 1.Staphylococcal superantigen-like 10 inhibits CXCL12-induced human tumor cell migration.In vivo evolution of X4 human immunodeficiency virus type 1 variants in the natural course of infection coincides with decreasing sensitivity to CXCR4 antagonistsBacterial mimetics of endocrine secretory granules as immobilized in vivo depots for functional protein drugs.
P2860
Q24557545-FDDAD421-6B79-4CBD-8B5B-12D6A29C85C1Q28252518-DCCBDEB6-712E-486A-9401-EEF21BDFFF39Q28257799-05987380-DA35-4438-8DF9-F937C4DD18AAQ28646673-4D3D5BC6-C3A5-4022-9091-63F15A72A041Q33803979-D15FB022-701E-48F8-B158-2EFA81A73524Q34346351-06D808BA-F3EC-497A-BC20-B70AAD563B2CQ35020718-65C2233A-CC68-4C88-B4E0-858F106AEABFQ36176102-5BCDCCE8-D4AC-4C3C-B166-979CA6076743Q36217242-49D4EB64-8D1B-4E2D-BDCD-9F2C59E715BDQ36514316-E908B2DB-AF7D-4220-A811-2609B3221FA6Q37247686-A141A588-7478-4262-B910-42228AB5E4A4Q37352728-93137C39-A317-44CB-90CA-56C555E6573AQ39616956-5467F447-F9B1-4FAC-8AF4-21D727CEFEA0Q39869145-9789B184-404A-4589-8DE7-FB9CF2C383B7Q40584611-B3372EB3-23BB-4871-A562-8058B7C0D71CQ41545294-44DD35E9-F261-42B3-8918-9A68CCEC364C
P2860
Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Inhibitory mechanism of the CX ...... iciency virus type 1 infection
@nl
Inhibitory mechanism of the CX ...... ciency virus type 1 infection.
@ast
Inhibitory mechanism of the CX ...... ciency virus type 1 infection.
@en
type
label
Inhibitory mechanism of the CX ...... iciency virus type 1 infection
@nl
Inhibitory mechanism of the CX ...... ciency virus type 1 infection.
@ast
Inhibitory mechanism of the CX ...... ciency virus type 1 infection.
@en
prefLabel
Inhibitory mechanism of the CX ...... iciency virus type 1 infection
@nl
Inhibitory mechanism of the CX ...... ciency virus type 1 infection.
@ast
Inhibitory mechanism of the CX ...... ciency virus type 1 infection.
@en
P2093
P2860
P3181
P1433
P1476
Inhibitory mechanism of the CX ...... iciency virus type 1 infection
@en
P2093
A Matsumoto
H Tamamura
N Yamamoto
S C Peiper
S Minoguchi
P2860
P304
P3181
P407
P577
1999-09-01T00:00:00Z